Survey on REKOVELLE Pen Injection for Controlled Ovarian Stimulation in Assisted Reproductive Technologies such as IVF and ICSI

What this Trial Is About

This research focuses on women undergoing assisted reproduction techniques such as in vitro fertilization IVF or intracytoplasmic sperm injection ICSI. It evaluates the use of REKOVELLE Pen, a drug used for controlled ovarian stimulation to develop multiple eggs for these fertility treatments. The study is observational and collects data about the drugs use in real-world clinical settings. Participants in this survey have received REKOVELLE Pen injections at doses of 12 mcg, 36 mcg, or 72 mcg for controlled ovarian stimulation. The research monitors the administration and use of this drug during the process of assisted reproduction. There are no separate study arms or placebo groups since this is an observational study. Participants provide information about their treatment experience, and researchers track adverse events from the start of drug administration until one week after egg collection or six weeks after embryo transfer if performed. The study collects data during usual clinical care to understand how the drug performs in practice. Participation lasts throughout the treatment cycle and follow-up periods as described.

REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)